Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$2.72
-0.16-5.56%
At close: -
$2.73
0.010000.37%
After Hours: 7:36 PM EDT
Comments
Loading...
Rocket Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:RCKT | Benzinga
Rocket Pharmaceuticals Inc has a consensus price target of $29.52 based on the ratings of 22 analysts. The high is $75 issued by Evercore ISI Group on September 30, 2022. The low is $2.5 issued by Jefferies on May 28, 2025. The 3 most-recent analyst ratings were released by UBS, Canaccord Genuity, and B of A Securities on June 17, 2025, June 3, 2025, and May 28, 2025, respectively. With an average price target of $8.33 between UBS, Canaccord Genuity, and B of A Securities, there's an implied 205.25% upside for Rocket Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
UBS
Canaccord Genuity
B of A Securities
BMO Capital
Scotiabank
1calculated from analyst ratings
Analyst Ratings for Rocket Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/17/2025 | Buy Now | 83.15% | UBS | Colin Bristow39% | $12 → $5 | Maintains | Buy | Get Alert |
| 06/03/2025 | Buy Now | 302.93% | Canaccord Genuity | Whitney Ijem56% | $34 → $11 | Maintains | Buy | Get Alert |
| 05/28/2025 | Buy Now | 229.67% | B of A Securities | Jason Zemansky77% | $32 → $9 | Maintains | Buy | Get Alert |
| 05/28/2025 | Buy Now | 193.04% | BMO Capital | Kostas Biliouris34% | $30 → $8 | Maintains | Outperform | Get Alert |
| 05/28/2025 | Buy Now | 595.97% | Scotiabank | Greg Harrison47% | $51 → $19 | Maintains | Sector Outperform | Get Alert |
| 05/28/2025 | Buy Now | 193.04% | Leerink Partners | Mani Foroohar50% | $37 → $8 | Downgrade | Outperform → Market Perform | Get Alert |
| 05/28/2025 | Buy Now | 522.71% | Chardan Capital | Geulah Livshits47% | $46 → $17 | Maintains | Buy | Get Alert |
| 05/28/2025 | Buy Now | -8.42% | Jefferies | Andrew Tsai30% | $29 → $2.5 | Downgrade | Buy → Hold | Get Alert |
| 05/27/2025 | Buy Now | 1438.46% | Needham | Gil Blum51% | $42 → $42 | Downgrade | Buy → Hold | Get Alert |
| 05/16/2025 | Buy Now | 998.9% | Cantor Fitzgerald | Josh Schimmer55% | $20 → $30 | Maintains | Overweight | Get Alert |
| 05/16/2025 | Buy Now | 1072.16% | Wedbush | Yun Zhong38% | $32 → $32 | Reiterates | Outperform → Outperform | Get Alert |
| 05/16/2025 | Buy Now | 1584.98% | Chardan Capital | Geulah Livshits47% | $45 → $46 | Maintains | Buy | Get Alert |
| 05/12/2025 | Buy Now | 1768.13% | Scotiabank | Greg Harrison47% | $52 → $51 | Maintains | Sector Outperform | Get Alert |
| 05/12/2025 | Buy Now | 1145.42% | Canaccord Genuity | Whitney Ijem56% | $36 → $34 | Maintains | Buy | Get Alert |
| 05/09/2025 | Buy Now | 1548.35% | Chardan Capital | Geulah Livshits47% | $54 → $45 | Maintains | Buy | Get Alert |
| 05/09/2025 | Buy Now | 1511.72% | JP Morgan | Eric Joseph44% | $45 → $44 | Maintains | Overweight | Get Alert |
| 05/09/2025 | Buy Now | 376.19% | Goldman Sachs | Richard Law46% | $15 → $13 | Maintains | Neutral | Get Alert |
| 04/09/2025 | Buy Now | 1438.46% | Needham | Gil Blum51% | $42 → $42 | Reiterates | Buy → Buy | Get Alert |
| 03/12/2025 | Buy Now | 1731.5% | BMO Capital | Kostas Biliouris34% | → $50 | Initiates | → Outperform | Get Alert |
| 03/03/2025 | Buy Now | 1804.76% | Scotiabank | Greg Harrison47% | $51 → $52 | Maintains | Sector Outperform | Get Alert |
| 03/03/2025 | Buy Now | 449.45% | Goldman Sachs | Richard Law46% | $29 → $15 | Maintains | Neutral | Get Alert |
| 03/03/2025 | Buy Now | 1218.68% | Canaccord Genuity | Whitney Ijem56% | $39 → $36 | Maintains | Buy | Get Alert |
| 02/28/2025 | Buy Now | 1878.02% | Chardan Capital | Geulah Livshits47% | $62 → $54 | Maintains | Buy | Get Alert |
| 02/28/2025 | Buy Now | 1438.46% | Needham | Gil Blum51% | $52 → $42 | Maintains | Buy | Get Alert |
| 12/18/2024 | Buy Now | 962.27% | Jefferies | Andrew Tsai30% | → $29 | Initiates | → Buy | Get Alert |
| 11/19/2024 | Buy Now | 1328.57% | Canaccord Genuity | Whitney Ijem56% | $39 → $39 | Maintains | Buy | Get Alert |
| 11/19/2024 | Buy Now | 1511.72% | Leerink Partners | Mani Foroohar50% | $46 → $44 | Maintains | Outperform | Get Alert |
| 11/19/2024 | Buy Now | 2280.95% | Cantor Fitzgerald | Josh Schimmer55% | $65 → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 11/19/2024 | Buy Now | 1804.76% | Needham | Gil Blum51% | $52 → $52 | Reiterates | Buy → Buy | Get Alert |
| 11/18/2024 | Buy Now | 2171.06% | Chardan Capital | Geulah Livshits47% | $62 → $62 | Maintains | Buy | Get Alert |
| 11/11/2024 | Buy Now | 2171.06% | Chardan Capital | Geulah Livshits47% | $62 → $62 | Maintains | Buy | Get Alert |
| 11/08/2024 | Buy Now | 1804.76% | Needham | Gil Blum51% | $52 → $52 | Reiterates | Buy → Buy | Get Alert |
| 10/16/2024 | Buy Now | 1731.5% | Scotiabank | Greg Harrison47% | → $50 | Initiates | → Sector Outperform | Get Alert |
| 09/30/2024 | Buy Now | 1291.94% | Canaccord Genuity | Whitney Ijem56% | $38 → $38 | Maintains | Buy | Get Alert |
| 09/17/2024 | Buy Now | 1804.76% | Needham | Gil Blum51% | $52 → $52 | Reiterates | Buy → Buy | Get Alert |
| 08/06/2024 | Buy Now | 1878.02% | JP Morgan | Eric Joseph44% | $50 → $54 | Maintains | Overweight | Get Alert |
| 08/06/2024 | Buy Now | 2280.95% | Cantor Fitzgerald | Josh Schimmer55% | $65 → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 08/06/2024 | Buy Now | 2171.06% | Chardan Capital | Geulah Livshits47% | $62 → $62 | Maintains | Buy | Get Alert |
| 08/06/2024 | Buy Now | 1804.76% | Needham | Gil Blum51% | $52 → $52 | Reiterates | Buy → Buy | Get Alert |
| 07/03/2024 | Buy Now | 1365.2% | Canaccord Genuity | Whitney Ijem56% | $49 → $40 | Maintains | Buy | Get Alert |
| 06/28/2024 | Buy Now | 2171.06% | Chardan Capital | Geulah Livshits47% | $62 → $62 | Maintains | Buy | Get Alert |
| 06/28/2024 | Buy Now | 1804.76% | Needham | Gil Blum51% | $53 → $52 | Maintains | Buy | Get Alert |
| 05/07/2024 | Buy Now | 1841.39% | Needham | Gil Blum51% | $53 → $53 | Reiterates | Buy → Buy | Get Alert |
| 04/10/2024 | Buy Now | 1841.39% | Needham | Gil Blum51% | $53 → $53 | Reiterates | Buy → Buy | Get Alert |
| 04/02/2024 | Buy Now | 1328.57% | Goldman Sachs | Richard Law46% | → $39 | Initiates | → Neutral | Get Alert |
| 03/01/2024 | Buy Now | 1878.02% | UBS | Colin Bristow39% | $56 → $54 | Maintains | Buy | Get Alert |
| 02/27/2024 | Buy Now | 1731.5% | JP Morgan | Eric Joseph44% | $55 → $50 | Maintains | Overweight | Get Alert |
| 02/27/2024 | Buy Now | 2280.95% | Cantor Fitzgerald | Josh Schimmer55% | $65 → $65 | Maintains | Overweight | Get Alert |
| 02/13/2024 | Buy Now | 1841.39% | Needham | Gil Blum51% | $53 → $53 | Reiterates | Buy → Buy | Get Alert |
| 01/31/2024 | Buy Now | 2280.95% | Cantor Fitzgerald | Louise Chen57% | $65 → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 11/07/2023 | Buy Now | 1841.39% | Needham | Gil Blum51% | → $53 | Reiterates | Buy → Buy | Get Alert |
| 10/24/2023 | Buy Now | 2280.95% | Cantor Fitzgerald | Josh Schimmer55% | → $65 | Initiates | → Overweight | Get Alert |
| 09/13/2023 | Buy Now | 1658.24% | Stifel | Dae Gon Ha49% | → $48 | Reiterates | Buy → Buy | Get Alert |
| 09/13/2023 | Buy Now | 1841.39% | Needham | Gil Blum51% | $60 → $53 | Maintains | Buy | Get Alert |
| 08/11/2023 | Buy Now | 1621.61% | Canaccord Genuity | Whitney Ijem56% | $49 → $47 | Maintains | Buy | Get Alert |
| 08/11/2023 | Buy Now | 2134.43% | Chardan Capital | Geulah Livshits47% | → $61 | Reiterates | Buy → Buy | Get Alert |
| 08/10/2023 | Buy Now | 2097.8% | Needham | Gil Blum51% | → $60 | Reiterates | Buy → Buy | Get Alert |
| 08/10/2023 | Buy Now | 1658.24% | Stifel | Dae Gon Ha49% | $53 → $48 | Maintains | Buy | Get Alert |
| 05/23/2023 | Buy Now | 2097.8% | Needham | Gil Blum51% | → $60 | Reiterates | Buy → Buy | Get Alert |
| 05/08/2023 | Buy Now | 2134.43% | Chardan Capital | Geulah Livshits47% | $63 → $61 | Maintains | Buy | Get Alert |
| 05/05/2023 | Buy Now | 1182.05% | Raymond James | Steven Seedhouse57% | $33 → $35 | Maintains | Outperform | Get Alert |
| 05/05/2023 | Buy Now | 2097.8% | Needham | Gil Blum51% | → $60 | Reiterates | → Buy | Get Alert |
| 04/19/2023 | Buy Now | 2097.8% | Needham | Gil Blum51% | → $60 | Reiterates | → Buy | Get Alert |
| 03/01/2023 | Buy Now | 2207.69% | Chardan Capital | Geulah Livshits47% | $65 → $63 | Reiterates | → Buy | Get Alert |
| 02/28/2023 | Buy Now | 2097.8% | Needham | Gil Blum51% | → $60 | Reiterates | → Buy | Get Alert |
| 02/01/2023 | Buy Now | 1548.35% | Morgan Stanley | Michael Ulz66% | → $45 | Initiates | → Overweight | Get Alert |
| 01/23/2023 | Buy Now | 1694.87% | SVB Leerink | Mani Foroohar50% | $50 → $49 | Maintains | Outperform | Get Alert |
| 12/23/2022 | Buy Now | 1182.05% | B of A Securities | Greg Harrison47% | $38 → $35 | Maintains | Buy | Get Alert |
| 12/22/2022 | Buy Now | 1731.5% | SVB Leerink | Mani Foroohar50% | $54 → $50 | Maintains | Outperform | Get Alert |
| 12/06/2022 | Buy Now | 1878.02% | SVB Leerink | Mani Foroohar50% | $56 → $54 | Maintains | Outperform | Get Alert |
| 11/08/2022 | Buy Now | 1841.39% | Canaccord Genuity | Whitney Ijem56% | → $53 | Initiates | → Buy | Get Alert |
| 11/07/2022 | Buy Now | 1108.79% | Raymond James | Steven Seedhouse57% | $34 → $33 | Maintains | Outperform | Get Alert |
| 11/04/2022 | Buy Now | 2097.8% | Needham | Gil Blum51% | $62 → $60 | Maintains | Buy | Get Alert |
| 11/01/2022 | Buy Now | 1182.05% | BTIG | Yun Zhong38% | → $35 | Initiates | → Buy | Get Alert |
| 10/03/2022 | Buy Now | 2280.95% | Chardan Capital | Geulah Livshits47% | $62 → $65 | Maintains | Buy | Get Alert |
| 10/03/2022 | Buy Now | 1145.42% | Raymond James | Steven Seedhouse57% | $24 → $34 | Maintains | Outperform | Get Alert |
| 09/30/2022 | Buy Now | 2097.8% | SVB Leerink | Mani Foroohar50% | $65 → $60 | Maintains | Outperform | Get Alert |
| 09/30/2022 | Buy Now | 2647.25% | Evercore ISI Group | Joshua Schimmer45% | $65 → $75 | Maintains | Outperform | Get Alert |
| 09/27/2022 | Buy Now | 2171.06% | UBS | Colin Bristow39% | $68 → $62 | Maintains | Buy | Get Alert |
| 08/09/2022 | Buy Now | 779.12% | Raymond James | Steven Seedhouse57% | $22 → $24 | Maintains | Outperform | Get Alert |
| 07/26/2022 | Buy Now | 1951.28% | Stifel | Dae Gon Ha49% | $67 → $56 | Maintains | Buy | Get Alert |
| 07/08/2022 | Buy Now | 705.86% | Raymond James | Timur Ivannikov37% | → $22 | Initiates | → Outperform | Get Alert |
| 07/06/2022 | Buy Now | 2244.32% | SVB Leerink | Mani Foroohar50% | $66 → $64 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Rocket Pharmaceuticals (RCKT) stock?
The latest price target for Rocket Pharmaceuticals (NASDAQ:RCKT) was reported by UBS on June 17, 2025. The analyst firm set a price target for $5.00 expecting RCKT to rise to within 12 months (a possible 83.15% upside). 42 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Rocket Pharmaceuticals (RCKT)?
The latest analyst rating for Rocket Pharmaceuticals (NASDAQ:RCKT) was provided by UBS, and Rocket Pharmaceuticals maintained their buy rating.
When was the last upgrade for Rocket Pharmaceuticals (RCKT)?
There is no last upgrade for Rocket Pharmaceuticals
When was the last downgrade for Rocket Pharmaceuticals (RCKT)?
The last downgrade for Rocket Pharmaceuticals Inc happened on May 28, 2025 when Leerink Partners changed their price target from $37 to $8 for Rocket Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Rocket Pharmaceuticals (RCKT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Rocket Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Rocket Pharmaceuticals was filed on June 17, 2025 so you should expect the next rating to be made available sometime around June 17, 2026.
Is the Analyst Rating Rocket Pharmaceuticals (RCKT) correct?
While ratings are subjective and will change, the latest Rocket Pharmaceuticals (RCKT) rating was a maintained with a price target of $12.00 to $5.00. The current price Rocket Pharmaceuticals (RCKT) is trading at is $2.73, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
